Skip to main content
Clinical Trials/NCT05298072
NCT05298072
Unknown
Not Applicable

Identification of Novel Inflammation-related Biomarkers for Early Detection of Anthracycline-induced Cardiotoxicity in Breast Cancer Patients

University Hospital, Essen0 sites180 target enrollmentApril 2022

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Cardiotoxicity
Sponsor
University Hospital, Essen
Enrollment
180
Primary Endpoint
Cardiotoxicity during observational period
Last Updated
4 years ago

Overview

Brief Summary

This study aims to identify possible set of inflammatory biomarkers before, during and after anthracycline-based chemotherapy in breast cancer patients to identify (sub)clinical chemotherapy-related cardiac dysfunctionCRCD to identify patients who would benefit from additional cardioprotective therapy.

Registry
clinicaltrials.gov
Start Date
April 2022
End Date
December 2023
Last Updated
4 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
University Hospital, Essen
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • initial diagnosis of breast cancer
  • planned Anthracycline-based therapy
  • first-line chemotherapy
  • first visit before initiation of chemotherapy

Exclusion Criteria

  • previous chemotherapy
  • medical history of cardiac disease
  • inflammation-modulating medication
  • medication with RAS inhibitors
  • pregnancy
  • autoimmune disease
  • drug addictions
  • unwilling or unable to provide informed consent

Outcomes

Primary Outcomes

Cardiotoxicity during observational period

Time Frame: continuous evaluation during observational period of 12 months

Defined according to IC-OS 2021 Consensus Criteria

Similar Trials